{"denoms":[{"counts":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"101"}],"units":"Participants"}],"groups":[{"description":"Patients receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\naMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.","id":"BG000","title":"aMIL Arm"},{"description":"Patients do not receive activated Marrow Infiltrating Lymphocytes (aMIL)\n\nNo aMIL: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.","id":"BG001","title":"No aMIL"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"35.0","upperLimit":"74.8","value":"62.5"},{"groupId":"BG001","lowerLimit":"37.1","upperLimit":"75.9","value":"59.0"},{"groupId":"BG002","lowerLimit":"35.0","upperLimit":"75.9","value":"61.7"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"51"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"50"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"22"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"74"}]}],"title":"White"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"31"},{"groupId":"BG002","value":"101"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"86"}],"title":"Newly Diagnosed"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"}],"title":"Relapsed"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"}],"title":"High Risk"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"40"}],"title":"Low Risk"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"10"}],"title":"N/A"},{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"35"}],"title":"Indeterminate"}]}],"description":"The Myeloma Prognostic Risk Signature (MyPRS®) (Signal Genetics™) is used to estimate the underlying activity of disease progression in patients diagnosed with active multiple myeloma.","paramType":"COUNT_OF_PARTICIPANTS","title":"Myeloma Prognostic Risk Signature (MYPRS) Risk Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"85"}],"title":"Not High Risk"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"}],"title":"High Risk"}]}],"description":"The 70-gene Prognostic Risk Score (GEP-70) quantifies the expression of 70 genes commonly altered in multiple myeloma. Primarily prognostic, GEP-70 assesses risk of disease relapse and survival outcomes and is the randomization stratification of the MYPRS multiple myeloma specific gene expression profile risk categories.","paramType":"COUNT_OF_PARTICIPANTS","title":"70-gene expression Prognostic Risk Score (GEP-70)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"34"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"55"}],"title":"1 or 2"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"12"}],"title":"Missing"}]}],"description":"ECOG Scoring System\n\n0= Fully active, able to carry on all pre-disease performance without restriction\n\n1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work\n2. Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours\n3. Capable of only limited self care, confined to bed or chair more than 50% of waking hours\n4. Completely disabled. Cannot carry on any self care. Totally confined to bed or chair\n5. Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"30"}],"title":"Stage I"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"26"}],"title":"Stage II"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"25"}],"title":"Stage III"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"20"}],"title":"missing"}]}],"description":"Prognosticates the severity of multiple myeloma and patient survival based on routinely obtained lab values.\n\nStage I= Serum β2 microglobulin \\< 3.5 mg/l; serum albumin ≥ 3.5 g/dl; standard-risk chromosomal abnormalities (CA) and normal lactate dehydrogenase (LDH) Stage II= not stage I or Stage III Stage III= Serum β2 microglobulin ≥ 5.5 mg/L and either high-risk CA by florescent in situ hybridization (FISH) or high LDH","paramType":"COUNT_OF_PARTICIPANTS","title":"International Staging System (ISS) Multiple Myeloma Classification","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"9"}],"title":"IA-IB"},{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"21"}],"title":"IIA-IIB"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"56"}],"title":"IIIA-IIIB"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"}],"title":"missing"}]}],"description":"demonstrates the correlation between the amount of myeloma and the damage it has caused based on number of bone lesions, anemia, serum calcium levels, and serum and urine light chain levels, and can be measured as myeloma cell mass (myeloma cells in billions/m2)\\* .\n\nStage I= low cell mass (600 billion) Stage II= intermediate cell mass (600-1200 billion) Stage III= high cell mass (\\>1200 billion)\n\nSubcategory:\n\nA = normal renal function. B= abnormal renal function","paramType":"COUNT_OF_PARTICIPANTS","title":"Salmon Stage multiple myeloma classification","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"6","value":"1"},{"groupId":"BG001","lowerLimit":"1","upperLimit":"5","value":"2"},{"groupId":"BG002","lowerLimit":"1","upperLimit":"6","value":"1"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Number of Prior Multiple Myeloma Treatments","unitOfMeasure":"prior treatments"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.07","upperLimit":"8.15","value":"0.53"},{"groupId":"BG001","lowerLimit":"0.38","upperLimit":"4.80","value":"0.76"},{"groupId":"BG002","lowerLimit":"0.07","upperLimit":"8.15","value":"0.55"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Time to Diagnosis","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"35.0","upperLimit":"403.0","value":"63.0"},{"groupId":"BG001","lowerLimit":"33.0","upperLimit":"246.0","value":"56.0"},{"groupId":"BG002","lowerLimit":"33.0","upperLimit":"403.0","value":"60.0"}]}]}],"dispersionType":"INTER_QUARTILE_RANGE","paramType":"MEDIAN","title":"Time to stem cell transplant (SCT)","unitOfMeasure":"Days"}]}